Clinical trial
Overactive Bladder Innovative Therapy Trial (OrBIT)
NCT00448175 · Uroplasty, Inc, Industry · Completed
Key facts
| NCT number | NCT00448175 |
|---|---|
| Title | Overactive Bladder Innovative Therapy Trial (OrBIT) |
| Official title | Overactive Bladder Innovative Therapy Trial |
| Acronym | OrBIT |
| Lead sponsor | Uroplasty, Inc, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Device, Drug |
| Interventions | Urgent PC Neuromodulation System, Tolterodine |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 16, 2007 |
| Last update posted | May 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: